Publications by authors named "Kenneth C Anderson"

100Publications

Multiple myeloma: the (r)evolution of current therapy and a glance into future.

Haematologica 2020 Jul 23;105(10):2358-2367. Epub 2020 Jul 23.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.247015DOI Listing
July 2020

Multiple myeloma: the (r)evolution of current therapy and a glance into future.

Haematologica 2020 Jul 23. Epub 2020 Jul 23.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.247015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556665PMC
July 2020

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

Leukemia 2020 Jul 6. Epub 2020 Jul 6.

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0951-5DOI Listing
July 2020

Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.

Clin Lymphoma Myeloma Leuk 2020 Oct 27;20(10):e652-e659. Epub 2020 May 27.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.014DOI Listing
October 2020

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.

Cancers (Basel) 2020 Jun 5;12(6). Epub 2020 Jun 5.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02138, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352710PMC
June 2020

Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.

Leukemia 2020 May 18. Epub 2020 May 18.

Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0865-2DOI Listing
May 2020

IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.

Eur J Haematol 2020 Sep 9;105(3):326-334. Epub 2020 Jun 9.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13440DOI Listing
September 2020

Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.

Mol Cancer Res 2020 Jul 20;18(7):1063-1073. Epub 2020 Apr 20.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-19-0852DOI Listing
July 2020

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.

Leukemia 2020 Apr 1. Epub 2020 Apr 1.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0809-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529681PMC
April 2020

Changing the Paradigm.

Oncology (Williston Park) 2020 Mar 19;34(3). Epub 2020 Mar 19.

View Article

Download full-text PDF

Source
March 2020

The safety of current and emerging therapies for multiple myeloma.

Expert Opin Drug Saf 2020 Mar 3;19(3):269-279. Epub 2020 Mar 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2020.1733968DOI Listing
March 2020

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

Leukemia 2020 08 14;34(8):2150-2162. Epub 2020 Feb 14.

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0745-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392808PMC
August 2020

Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Oncogene 2020 Mar 5;39(13):2786-2796. Epub 2020 Feb 5.

Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-020-1172-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132141PMC
March 2020

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Blood Adv 2020 01;4(1):181-190

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019000491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960456PMC
January 2020

The impact of response kinetics for multiple myeloma in the era of novel agents.

Blood Adv 2019 10;3(19):2895-2904

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019000432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784522PMC
October 2019

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.

Leukemia 2020 02 28;34(2):567-577. Epub 2019 Aug 28.

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0558-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132142PMC
February 2020

Insights into the management of older patients with multiple myeloma.

Clin Adv Hematol Oncol 2019 Jul;17(7):390-392

Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
July 2019

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

Blood Cancer J 2019 08 12;9(8):64. Epub 2019 Aug 12.

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0224-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690908PMC
August 2019

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.

Future Oncol 2019 Oct 9;15(28):3267-3281. Epub 2019 Aug 9.

Pfizer, New York, NY 10017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0368DOI Listing
October 2019

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Expert Opin Biol Ther 2019 11 11;19(11):1143-1156. Epub 2019 Jul 11.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1641196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785394PMC
November 2019

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Leukemia 2020 01 10;34(1):167-179. Epub 2019 Jun 10.

Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0498-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901818PMC
January 2020

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.

Leukemia 2019 11 8;33(11):2685-2694. Epub 2019 Apr 8.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0467-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783320PMC
November 2019

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Ann Transl Med 2018 Dec;6(Suppl 2):S93

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.11.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330615PMC
December 2018

Contribution of Inhibition of Protein Catabolism in Myeloma.

Cancer J 2019 Jan/Feb;25(1):11-18

From the Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000349DOI Listing
March 2020

PRMT5 inhibitors on the (myeloma) road.

Oncotarget 2018 Nov 30;9(94):36646-36647. Epub 2018 Nov 30.

Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291180PMC
November 2018

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.

Cell Rep 2018 12;25(13):3693-3705.e6

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; VA Boston Healthcare System, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.12.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407615PMC
December 2018

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):88-96

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.88DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245982PMC
November 2018

The power of proteasome inhibition in multiple myeloma.

Expert Rev Proteomics 2018 12 14;15(12):1033-1052. Epub 2018 Nov 14.

b Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2018.1543595DOI Listing
December 2018

The biological significance of histone modifiers in multiple myeloma: clinical applications.

Blood Cancer J 2018 08 22;8(9):83. Epub 2018 Aug 22.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0119-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127133PMC
August 2018

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Front Immunol 2018 10;9:1822. Epub 2018 Aug 10.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095980PMC
September 2019

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Front Immunol 2018 10;9:1821. Epub 2018 Aug 10.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, United States.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.01821
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.01821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095983PMC
September 2019

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Leukemia 2019 02 22;33(2):426-438. Epub 2018 Aug 22.

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0242-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367000PMC
February 2019

Promise of Immune Therapies in Multiple Myeloma.

J Oncol Pract 2018 07;14(7):411-413

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045492PMC
July 2018

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Br J Haematol 2018 08 29;182(4):495-503. Epub 2018 May 29.

Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105456PMC
August 2018

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Br J Haematol 2018 05 10;181(4):433-446. Epub 2018 May 10.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15116DOI Listing
May 2018

Meaningful changes in end-of-life care among patients with myeloma.

Haematologica 2018 08 10;103(8):1380-1389. Epub 2018 May 10.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.187609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068022PMC
August 2018

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Ann Hematol 2018 May 23;97(5):839-849. Epub 2018 Jan 23.

Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies', Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3237-5DOI Listing
May 2018

Targeting CD38 alleviates tumor-induced immunosuppression.

Oncotarget 2017 Dec 26;8(68):112166-112167. Epub 2017 Dec 26.

The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22992DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762499PMC
December 2017

The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Nat Rev Clin Oncol 2018 04 9;15(4):219-233. Epub 2018 Jan 9.

Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.197DOI Listing
April 2018

Should minimal residual disease negativity be the end point of myeloma therapy?

Blood Adv 2017 Mar 14;1(8):517-521. Epub 2017 Mar 14.

Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2016000117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728451PMC
March 2017

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Future Oncol 2018 May 22;14(11):1035-1047. Epub 2017 Dec 22.

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0616DOI Listing
May 2018

The proteasome and proteasome inhibitors in multiple myeloma.

Cancer Metastasis Rev 2017 12;36(4):561-584

Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9707-8DOI Listing
December 2017

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

J Clin Oncol 2018 01 28;36(3):283-299. Epub 2017 Nov 28.

Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.1734DOI Listing
January 2018

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

J Oncol Pract 2018 02 28;14(2):129-133. Epub 2017 Nov 28.

Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; American Society of Clinical Oncology, Alexandria, VA; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.2017.028902
Publisher Site
http://dx.doi.org/10.1200/JOP.2017.028902DOI Listing
February 2018

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Expert Opin Pharmacother 2017 Dec 1;18(18):1975-1985. Epub 2017 Dec 1.

d Blood and Marrow Transplant Program , Roswell Park Cancer Institute , Buffalo , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1409207DOI Listing
December 2017

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Antibodies (Basel) 2017 Nov 14;6(4). Epub 2017 Nov 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/antib6040018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698817PMC
November 2017

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Oncotarget 2017 Oct 5;8(46):80109-80123. Epub 2017 Jul 5.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.19019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655183PMC
October 2017

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.

Cell Chem Biol 2017 12 19;24(12):1490-1500.e11. Epub 2017 Oct 19.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2017.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749250PMC
December 2017